Literature DB >> 20947650

Minimally important change in a Parent-Proxy Quality-of-Life questionnaire for pediatric chronic cough.

Peter A Newcombe1, Jeanie K Sheffield2, Anne B Chang3.   

Abstract

BACKGROUND: The Parent Cough-Specific Quality-of-Life questionnaire (PC-QOL) has relevance and clinical utility as a cough-specific QOL measure for pediatric use. Its validity has been demonstrated. This study sought to determine the minimally important difference (MID) for the PC-QOL completed by parents of young children with chronic cough.
METHOD: Thirty-four children (22 boys, 12 girls; median age, 26.5 months; interquartile range, 17.3-38.8 months) and their mothers participated. Mothers completed a cough-related measure (verbal category descriptive score) and the PC-QOL on two occasions separated by 2 to 3 weeks. Two approaches were used to calculate MID.
RESULTS: Distribution-based approaches to estimating MID resulted in ranges of 0.50 to 0.78 (effect size method), 0.30 to 0.48 (SE of measurement method), and 0.60 to 0.69 (one-half SD method) for PC-QOL overall and domain scales. Based on verbal category descriptive score change, an anchor-based approach resulted in an MID estimate of 0.9 for overall PC-QOL change and ranged from 0.71 to 0.95 for individual domain PC-QOL change.
CONCLUSION: An MID for the PC-QOL of 0.9 is recommended in interpreting health status change in children with chronic cough and will aid clinicians and researchers in interpreting health-related QOL changes following treatments and clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20947650     DOI: 10.1378/chest.10-1476

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

1.  Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.

Authors:  Louis-Philippe Boulet; Remy R Coeytaux; Douglas C McCrory; Cynthia T French; Anne B Chang; Surinder S Birring; Jaclyn Smith; Rebecca L Diekemper; Bruce Rubin; Richard S Irwin
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

2.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

Review 3.  Review: Quality of Life in Children with Non-cystic Fibrosis Bronchiectasis.

Authors:  Anna Marie Nathan; Jessie Anne de Bruyne; Kah Peng Eg; Surendran Thavagnanam
Journal:  Front Pediatr       Date:  2017-04-24       Impact factor: 3.418

4.  Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Robert S Ware; Catherine A Byrnes; Peter S Morris; I Brent Masters; Gabrielle B McCallum; Michael J Binks; Heidi Smith-Vaughan; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; André Schultz; Mark Chatfield; Paul J Torzillo; Anne B Chang
Journal:  Lancet Respir Med       Date:  2019-08-16       Impact factor: 30.700

5.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

6.  Does additional antimicrobial treatment have a better effect on URTI cough resolution than homeopathic symptomatic therapy alone? A real-life preliminary observational study in a pediatric population.

Authors:  Alessandro Zanasi; Salvatore Cazzato; Massimiliano Mazzolini; Carla Maria Sofia Ierna; Marianna Mastroroberto; Elena Nardi; Antonio Maria Morselli-Labate
Journal:  Multidiscip Respir Med       Date:  2015-08-07

Review 7.  An underestimated cause of chronic cough: The Protracted Bacterial Bronchitis.

Authors:  Paola Di Filippo; Alessandra Scaparrotta; Marianna Immacolata Petrosino; Marina Attanasi; Sabrina Di Pillo; Francesco Chiarelli; Angelika Mohn
Journal:  Ann Thorac Med       Date:  2018 Jan-Mar       Impact factor: 2.219

Review 8.  How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods.

Authors:  Yosra Mouelhi; Elisabeth Jouve; Christel Castelli; Stéphanie Gentile
Journal:  Health Qual Life Outcomes       Date:  2020-05-12       Impact factor: 3.186

Review 9.  Protracted bacterial bronchitis: The last decade and the road ahead.

Authors:  Anne B Chang; John W Upham; I Brent Masters; Gregory R Redding; Peter G Gibson; Julie M Marchant; Keith Grimwood
Journal:  Pediatr Pulmonol       Date:  2015-12-04

10.  Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Catherine A Byrnes; Peter S Morris; I Brent Masters; Robert S Ware; Gabrielle B McCallum; Michael J Binks; Julie M Marchant; Peter van Asperen; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; Helen Petsky; Paul J Torzillo; Anne B Chang
Journal:  Lancet       Date:  2018-09-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.